Tim Van Hauwermeiren, argenx CEO
Argenx to retest Vyvgart in autoimmune platelet disease after failure last year
The Dutch biotech argenx has big plans to develop its drug Vyvgart in more than a dozen autoimmune diseases. But failures in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
